Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022969 | 1.00 | ACE (0.48) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL202300 | 1.00 | ACE (0.48) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL16187224 | 0.87 | ATM (0.45) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL14237836 | 0.87 | ATM (0.45) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL26077743 | 0.87 | ATM (0.45) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL1249539 | 0.87 | HSD17B10 (0.46) | ATMHSD17B10SMN1; SMN2USP2PREP | |
| SCHEMBL3509553 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL9879848 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL3509552 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL1021093 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101090631-A | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIV SOUTHERN CALIFORNIA (US) | 2007-12-19 | — | — | CN | claimed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | claimed |
| US-20250368637-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2025-12-04 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250170104-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| EP-4486452-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LASSS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024215870-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POLYMERASE THETA AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| WO-1992014732-A1 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| WO-1992001668-A1 | BENZOIC ACID SUBSTITUTED DERIVATIVES HAVING CARDIOVASCULAR ACTIVITY | ITALFARMACO S.P.A. (IT) | 1992-02-06 | — | — | WO | disclosed |
| EP-0213326-B1 | 2,5-DIMETHYL PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1991-03-06 | — | — | EP | disclosed |
| EP-0388909-A2 | Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0175363-B1 | 4,5-DIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4837225-A | ENCEPHALOTROPIC AND PSYCHOTROPIC EFFECTS | CASSELL AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| US-4816454-A | CARDIOVASCULAR DISORDERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1989-03-28 | — | — | US | disclosed |
| EP-0213326-A1 | 2,5-Dimethyl pyrrole derivatives, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ACE 621/4885ATM 3913/4885HSD17B10 3115/4885 |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | ACE 4837/4885ATM 1955/4885HSD17B10 2660/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ACE 621/4885ATM 3913/4885HSD17B10 3115/4885 |
| US-20250170104-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | LTA, SERPINB1, LAS1L | ACE 606/4885ATM 3938/4885HSD17B10 1790/4885 |
| US-20250368637-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | FAP, FIBP, DNPEP | ACE 50/4885ATM 3109/4885HSD17B10 4631/4885 |
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | ACE 30/4885ATM 4050/4885HSD17B10 4763/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ACE 621/4885ATM 3913/4885HSD17B10 3115/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | ACE 30/4885ATM 4050/4885HSD17B10 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.